Enhancement of empathy, creative thinking, and subjective well-being outlasts the intoxication.
Increased mindfulness and decreased anxiety, depression, and stress were seen right away, becoming more significant four weeks after dosing.
Recent research shows psychedelics may effectively increase creativity.
The context of the psychedelic experience plays a critical role in determining positive outcomes for patients.
The answer is yes and no. It's a matter of perspective.
The similarities between aeruginascin and other serotonin analogs may connect the dots between aeruginascin and Wood Lover Paralysis
Improvements in depression and anxiety are associated with greater intensity of mystical experiences and higher ratings of the spiritual significance and personal meaning.
Bruce Tobin is asking Health Canada to approve psilocybin to treat anxiety and depression in end-of-life patients.
FDA approval for psilocybin-assisted therapy for depression appears to be on the horizon.
Psilocybin-assisted therapy is showing promise for quitting smoking, but how does it work?